Application of dendritic cell vaccine immunotherapy in gynecologic malignancies
Authors:
- G. V. ZhukovaGZG. V. Zhukova
- E. M. FrantsiyantsEFE. M. Frantsiyants
- T. I. MoiseenkoTMT. I. Moiseenko
- A. P. MensheninaAMA. P. Menshenina
- A. I. ShikhlyarovaASA. I. Shikhlyarova
- V. A. BandovkinaVBV. A. Bandovkina
- E. I. SurikovaESE. I. Surikova
- E. V. ShalashnayaESE. V. Shalashnaya
- P. S. KachesovaPKP. S. Kachesova
- 17 December 2025
- journal article
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 6 (4) , 59-74
Abstract
The development of antitumor strategies aimed at restoring systemic and local immune regulation is considered one of the most promising directions. Technologies based on dendritic cell vaccines (DCVs), characterized by minimal toxicity and alignment with fundamental immunological mechanisms of antitumor resistance, are of particular interest. Purpose of the study . Is to evaluate the effectiveness of immunotherapeutic approaches for gynecologic malignancies using DCVs and to outline promising directions for further development. Materials and methods. A literature search was conducted in the bibliographic registers MEDLINE, ClinicalTrial.gov., eLIBRARY and CyberLeninka, using the search systems PubMed, Google Scholar. The vast majority of the identified sources are indexed in Scopus and Web of Science. The review includes more than 60 publications in Russian and English, over 50 % of which were published within the past five years. Results. The analysis summarizes data on the clinical outcomes of DCV-based therapy in advanced cervical cancer, endometrial cancer, and ovarian cancer. Reported beneficial effects include temporary disease stabilization, improved overall survival and quality of life in advanced malignancies, enhanced efficacy of subsequent chemotherapy, and occasional cases of partial or complete remission. The review also addresses potential reasons for the limited efficacy of DCVs, as well as possible combinations of this technology with other immunotherapeutic modalities and traditional anticancer treatments. The currently modest therapeutic effectiveness of DCVs in gynecologic cancers may be attributed both to the insufficient maturity of the technology and to inherent mechanisms of tumor immune evasion. Conclusion. The therapeutic potential of DCVs has not yet been fully realized. Advances in immunotherapy, molecular biology, nanotechnology, and strategies for activating systemic and local antitumor resistance mechanisms provide a foundation for defining future research priorities aimed at improving the efficacy of DCVs as an important component of multimodal treatment for gynecologic malignancies.Keywords
This publication has 55 references indexed in Scilit:
- A new era of cancer immunotherapy: vaccines and miRNAsCancer Immunology, Immunotherapy, 2025
- Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanismsCancer Communications, 2024
- Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapyJournal of Controlled Release, 2023
- Mast Cells in the Tumor Microenvironment2020
- Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancerCancer Immunology, Immunotherapy, 2018
- A case of advanced ovarian cancer effectively treated with a combination of multi-peptide dendritic cell immunotherapy, surgery, and chemotherapyPersonalized Medicine Universe, 2017
- Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastasesCancer Immunology, Immunotherapy, 2014
- Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL‐10European Journal of Immunology, 2014
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remissionCancer Immunology, Immunotherapy, 2011
- A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancerCancer Immunology, Immunotherapy, 2009